Seres Therapeutics

Seres Therapeutics is developing revolutionary microbiome-based therapeutics to treat serious diseases.
See our Twitter Guidelines here:

[Seres Therapeutics @SeresTX]

This morning we announced our Q1 2026 financial results and provided business updates.

Read the release: https://t.co/w9oQ6matgE

[Seres Therapeutics @SeresTX]

This morning we reported our Q4 and full year 2025 financial results and provided business updates.

Read more: https://t.co/YlNqZR1i2K

[Seres Therapeutics @SeresTX]

Today we announced the appointment of Richard Kender as Executive Chair and Interim CEO and provided additional corporate updates.

We will be hosting a conference call tomorrow, March 3, at 8:30 am ET.

More info: https://t.co/sW5SFrNjiC

[Seres Therapeutics @SeresTX]

We’re excited to share the publication of two manuscripts in @NatureMedicine and @JIDJournal highlighting new insights into the functional mechanism and clinical impact of VOWST™.

Read More: https://t.co/U6JehSi6cj

[Seres Therapeutics @SeresTX]

We’re looking forward to participating in a fireside chat at the Piper Sandler Healthcare Conference on December 2 at 10:30 AM EST.

Read more:https://t.co/nMxNzo4mva

[Seres Therapeutics @SeresTX]

This morning our team reported Q3 financial results and business updates. We will be holding a conference call at 8:30am EST – more details and dial-in information can be found in today’s press release: https://t.co/iVh8H5XF0p

[Seres Therapeutics @SeresTX]

Mark your calendars—our team will be sharing Q3 earnings and business updates next Wednesday, November 5 at 8:30am EST.

Details and conference call information can be found here: https://t.co/jXJZ5L0dMa

[Seres Therapeutics @SeresTX]

We’re excited to share that @CARB_X will provide Seres with up to $3.6M to support development and manufacturing of an oral liquid formulation of SER-155 for medically vulnerable patient populations who cannot be dosed with oral capsules.

https://t.co/xDBDhLVkCj

[Seres Therapeutics @SeresTX]

We’re looking forward to presenting at #IDWeek2025 in Atlanta next week! Dr. Tessa Andermann, Associate Professor of Medicine at UNC Chapel Hill, will share new post hoc data from our SER-155 Phase 1b trial.

Read more: https://t.co/js6j1GLwKt

[Seres Therapeutics @SeresTX]

The Seres management team will be attending the upcoming H.C. Wainwright Global Investment Conference in New York City and will present a company overview on September 8th at 3pm EST.

Read more: https://t.co/ojsdXeTI7B

[Seres Therapeutics @SeresTX]

This morning our team reported Q2 2025 financial results and business updates. We will also be holding a conference call at 8:30am EST, and a webcast will be available approximately two hours following the event.

Full release: https://t.co/8Hci7Yy5la

[Seres Therapeutics @SeresTX]

Mark your calendars—our team will be sharing Q2 earnings and business updates this Wednesday, August 6 at 8:30am EST.

Details and conference call information can be found here: https://t.co/dtUWCEv9wz

[Seres Therapeutics @SeresTX]

We’re excited to present new SER-155 Phase 1b exploratory biomarker data at #ASCO25. If you’re attending, we welcome you to stop by our poster and learn more!

Read more: https://t.co/k19Hlakp64

[Seres Therapeutics @SeresTX]

This morning we shared our Q1 results and business updates. SER-155 is planning for a Phase 2 following FDA feedback, with new exploratory biomarker data supporting its potential in BSIs and broader immune/inflammatory diseases. Strategic partnership discussions for SER-155 are underway.

https://t.co/XL4ftFxsLg

[Seres Therapeutics @SeresTX]

We’re looking forward to sharing our Q1 2025 financial results and business updates this Wednesday, May 7 at 8:30am EST.

Dial-in info can be found in our recent release: https://t.co/fID7y9SsDB

[Seres Therapeutics @SeresTX]

Digestive Disease Week is just around the corner! Our team will be presenting three posters highlighting new results that could help identify candidate biomarkers to support the further clinical development of live biotherapeutics to treat inflammatory and immune diseases, including ulcerative colitis and Crohn’s disease.

https://t.co/LyFVQrYKX8

[Seres Therapeutics @SeresTX]

Seres will be at #EBMT25 sharing data from our Phase 1b placebo-controlled study of SER-155 in allo-HSCT patients.

Poster abstract (A178): https://t.co/iUGdwiJ1EQ

Oral presentation abstract (OS16-01): https://t.co/IA6yk1og2c

[Seres Therapeutics @SeresTX]

This morning we reported Q4 and full year 2024 earnings. In addition, we shared updates regarding upcoming milestones for our lead live biotherapeutic, SER-155.

Read more in the full release: https://t.co/1ny1Vxo3u9

View the webcast replay: https://t.co/POTALPTjBN

[Seres Therapeutics @SeresTX]

Tomorrow morning our team will host a conference call and live video webcast to review our Q4 and full-year 2024 financial results, along with key business updates.

Check out our press release for dial-in info: https://t.co/8JsPKKf3hb

[Flagship Pioneering @FlagshipPioneer]

“We’ve got the right technology, the right team, the right science to change lives, and we're in the process of doing so.” @SeresTX CEO Eric Shaff explains how the company is building on its experience developing VOWST, the first-ever FDA-approved oral life biotherapeutic, as it pioneers new therapies like SER-155 to address unmet need in in allo-HSCT. His full CEO Chat here: https://t.co/p0U8F4ubTp

#FlagshipStudio #JPM25